Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1594

Sort by

Sort Order Select

Journal Articles

Morschhauser F, Feugier P, Flinn IW, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment of patients with diffuse large B-cell lymphoma. Blood. 2021;137(5):600-609.

Blood (2021) 137 (13): 1844.

https://doi.org/10.1182/blood.2021011330

Published: 2021

Journal Articles

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

Blood (2021) 137 (5): 600–609.

https://doi.org/10.1182/blood.2020006578

Published: 2021

Includes: Supplemental data

Journal Articles

The different flavors and splices of MCL

Oliver Weigert

Blood (2020) 136 (5): 526–527.

https://doi.org/10.1182/blood.2020005591

Published: 2020

Journal Articles

International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI

Amy S. Ruppert, Jesse G. Dixon, Gilles Salles, Anna Wall, David Cunningham, Viola Poeschel, Corinne Haioun, Herve Tilly, Herve Ghesquieres, Marita Ziepert, Jocelyne Flament, Christopher Flowers, Qian Shi, Norbert Schmitz

Blood (2020) 135 (23): 2041–2048.

https://doi.org/10.1182/blood.2019002729

Published: 2020

Includes: Supplemental data

Journal Articles

Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report

Stuart E. Lacy, Sharon L. Barrans, Philip A. Beer, Daniel Painter, Alexandra G. Smith, Eve Roman, Susanna L. Cooke, Camilo Ruiz, Paul Glover, Suzan J. L. Van Hoppe, Nichola Webster, Peter J. Campbell, Reuben M. Tooze, Russell Patmore, Cathy Burton, Simon Crouch, Daniel J. Hodson

Blood (2020) 135 (20): 1759–1771.

https://doi.org/10.1182/blood.2019003535

Published: 2020

Includes: Supplemental data

Journal Articles

High total metabolic tumor volume at baseline predicts survival independent of response to therapy

Blood (2020) 135 (16): 1396–1405.

https://doi.org/10.1182/blood.2019003526

Published: 2020

Includes: Supplemental data

Journal Articles

Early Follicular Lymphoma Progression in Patients Treated with Frontline Immunochemotherapy with/without Rituximab Maintenance: Clinically Meaningful Even in Chemosensitive Individuals

Vit K Prochazka, MD prof, David Belada, MD PhD, Andrea Janikova, MD PhD Assoc Prof, Katerina Benesova, MD PhD, Heidi Mocikova, MD PhD, Juraj Duras, MD, Robert Pytlik, MD PhD, Jan Pirnos, MD, Alice Sýkorová, MD PhD, Vit Campr, MD PhD, Jozef Michalka, MD, Kateřina Kopečková, MD PhD, Jitka Dlouha, Tomas Papajik, MD prof, Marek Trneny, MD prof

Blood (2019) 134 (Supplement_1): 3983.

https://doi.org/10.1182/blood-2019-129756

Published: 2019

Journal Articles

R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy

Rory McCulloch, FRCPath, MRCP, MBBS, Carlo Visco, Rebecca Frewin, Neil Phillips, Toby A. Eyre, David Tucker, MD, Francesca M. Quaglia, Annabel McMillan, Jonathan Lambert, Nicola Crosbie, Simon Rule

Blood (2019) 134 (Supplement_1): 3989.

https://doi.org/10.1182/blood-2019-129829

Published: 2019

Journal Articles

Transformation from Indolent Primary Cutaneous Marginal Zone Lymphoma to Aggressive Primary Cutaneous Diffuse Large B-Cell Lymphoma: A Rare Case and Review of the Literature

Emily Harris, Ariel Sindel, DO, Ian McConnell, William Clark, MDMS, Alden Chesney, MD, Victor Yazbeck, MD

Blood (2019) 134 (Supplement_1): 5266.

https://doi.org/10.1182/blood-2019-130921

Published: 2019

Journal Articles

R-CHOP Vs. R-CHOP+X for Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis

Oren Pasvolsky, MD, Alon Rozental, MD, Pia Raanani, MD, Anat Gafter-Gvili, MD, Ronit Gurion

Blood (2019) 134 (Supplement_1): 5331.

https://doi.org/10.1182/blood-2019-126013

Published: 2019

Journal Articles

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Shinya Rai, MD PhD, Koji Kato, MD PhD, Junji Suzumiya, MD PhD, Koji Izutsu, MD PhD, Momoko Nishikori, MD PhD, Hirohiko Shibayama, MD PhD, Yoshinobu Maeda, MD PhD, Kenichi Yoshimura, PhD, Ukihide Tateishi, MD PhD, Toshihiro Miyamoto, MD PhD, Jun Ishikawa, MD PhD, Tsutomu Takahashi, MD PhD, Takahiro Yamauchi, MD PhD, Koichi Akashi, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2019) 134 (Supplement_1): 5245.

https://doi.org/10.1182/blood-2019-126455

Published: 2019

Journal Articles

Dose Adjusted R-EPOCH Does Not Improve Outcomes in High Grade B Cell Lymphoma with Double Expressor Status or Gain of MYC/BCL2

Prue Hardefeldt, MBBS, John Moore, MDFRACP,FRCPA, Sam Milliken, MBBS, FRACP, FRCPA, Keith Fay, FRCP,FRCPath,MB, Lavee Orly, MBBS, Eleni Mayson, FRACP, FRCPA, MBBS, MPhil, Barbara Withers, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2019) 134 (Supplement_1): 5336.

https://doi.org/10.1182/blood-2019-125154

Published: 2019

Journal Articles

Engine: Phase III Randomized Study of Enzastaurin/R-CHOP Versus Placebo/R-CHOP in Frontline High Risk Diffuse Large B Cell Lymphoma Patients with Novel Genomic Biomarker DGM1

Jun Zhu, MD PhD, Grzegorz Nowakowski, MD, Qingyuan Zhang, Joshua Brody, MD, Xiuhua Sun, MD, Joseph Maly, MD, Yuqin Song, MD PhD, Yongping Song, MD PhD, Jennifer Kimberly Lue, MD, Wen Luo, PhD, Lei Zhang, MD, Isabel Han, Manoj Jivani, Young Liu, Ling Li, MD, Joan Sun, MBA, Stephen D. Smith, MD

Blood (2019) 134 (Supplement_1): 5330.

https://doi.org/10.1182/blood-2019-124930

Published: 2019

Journal Articles

AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Eliza A Hawkes, Kate Manos, MBBS, Charmaine Smith, Joanne Hawking, Stephanie O'Brien, Leonid Churilov, Joseph McKendrick, William Renwick, Andrew Grigg, Tom Witkowski, Andrew Scott, Sze-Ting Lee, Wendi Lin, Chun Fong, Carmela Rooney, Allison Barraclough, Joel Wight, Geoff Chong

Blood (2019) 134 (Supplement_1): 5332.

https://doi.org/10.1182/blood-2019-127858

Published: 2019

Journal Articles

Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Llarge B Cell Lymphoma

Xudong Zhang, Junxia Hu, Qingjiang Chen, Mingzhi Zhang, MD PhD, Ken H. Young

Blood (2019) 134 (Supplement_1): 5221.

https://doi.org/10.1182/blood-2019-128424

Published: 2019

Journal Articles

Etoposide Plays an Important Role in Treatment of Lymphoma Associated Hemophagocytic Lymphohistiocytosis

Yue Song, Yini Wang, Jingshi Wang, Zhao Wang, MD PhD

Blood (2019) 134 (Supplement_1): 5341.

https://doi.org/10.1182/blood-2019-132119

Published: 2019

Journal Articles

Relapsed Follicular Lymphoma and Haploidentical Transplantation Using Double Source of Hematopoietic Stem Cells and Post-Transplant Cyclophosphamide: Case Report

Ana Rojas Fonseca, Nelson Hamerschlak, MD PhD, José Salvador Rodrigues de Oliveira, MD PhD

Blood (2019) 134 (Supplement_1): 5718.

https://doi.org/10.1182/blood-2019-125208

Published: 2019

Journal Articles

EHMT2 Inhibitor BIX-01294 Induces Endoplasmic Reticulum Stress Mediated Apoptosis and Autophagy in Diffuse Large B Cell Lymphoma Cells

Linyan Xu, PhD, Xiang Gao, Wei Sang, MD, Dongmei Yan, Xuguang Song, Feng Zhu, Kailin Xu, MD

Blood (2019) 134 (Supplement_1): 2787.

https://doi.org/10.1182/blood-2019-127653

Published: 2019

Journal Articles

Highly Multiplexed Single Cell Spatial Analysis of the Tumor Microenvironment in Lymphoma Predicts Clinical Outcomes

Monirath Hav, PhD, Anthony Colombo, MS, Erik Gerdtsson, MS, Mohan Singh, PhD, Denaly Chen, MD, James Hicks, PhD, Peter Kuhn, PhD, Imran Siddiqi, MD PhD, Akil Merchant, MD

Blood (2019) 134 (Supplement_1): 2789.

https://doi.org/10.1182/blood-2019-130831

Published: 2019

Journal Articles

Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL

Eugene C Kim, PhD, Jinzhen Fan, PhD, Christopher R Bolen, PhD, Alexandra Bazeos, MD PhD FRCPath, Yanwen Jiang, PhD, Sandhya Balasubramanian, MS, Rama Balakrishnan, PhD, Andrea Knapp, PhD, Kathryn Humphrey, BSc, Tina G Nielsen, MD PhD, Jeffrey M. Venstrom, MD PhD, Genevive Hernandez, PhD, Joseph N Paulson, PhD

Blood (2019) 134 (Supplement_1): 2788.

https://doi.org/10.1182/blood-2019-124687

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Morschhauser F, Feugier P, Flinn IW, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment of patients with diffuse large B-cell lymphoma. Blood. 2021;137(5):600-609.

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

The different flavors and splices of MCL

International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI

Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report

High total metabolic tumor volume at baseline predicts survival independent of response to therapy

Early Follicular Lymphoma Progression in Patients Treated with Frontline Immunochemotherapy with/without Rituximab Maintenance: Clinically Meaningful Even in Chemosensitive Individuals

R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy

Transformation from Indolent Primary Cutaneous Marginal Zone Lymphoma to Aggressive Primary Cutaneous Diffuse Large B-Cell Lymphoma: A Rare Case and Review of the Literature

R-CHOP Vs. R-CHOP+X for Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Dose Adjusted R-EPOCH Does Not Improve Outcomes in High Grade B Cell Lymphoma with Double Expressor Status or Gain of MYC/BCL2

Engine: Phase III Randomized Study of Enzastaurin/R-CHOP Versus Placebo/R-CHOP in Frontline High Risk Diffuse Large B Cell Lymphoma Patients with Novel Genomic Biomarker DGM1

AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Llarge B Cell Lymphoma

Etoposide Plays an Important Role in Treatment of Lymphoma Associated Hemophagocytic Lymphohistiocytosis

Relapsed Follicular Lymphoma and Haploidentical Transplantation Using Double Source of Hematopoietic Stem Cells and Post-Transplant Cyclophosphamide: Case Report

EHMT2 Inhibitor BIX-01294 Induces Endoplasmic Reticulum Stress Mediated Apoptosis and Autophagy in Diffuse Large B Cell Lymphoma Cells

Highly Multiplexed Single Cell Spatial Analysis of the Tumor Microenvironment in Lymphoma Predicts Clinical Outcomes

Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only